Physician profile
Ali M Abbas
NPI 1144667999
$4,553.31
in general payments reported to CMS, 2019-2025
26 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2021: $121 · 2023: $794 · 2024: $1,474 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Education: $84.00 · Entertainment: $13.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.93 |
| Education | $84.00 |
| Entertainment | $13.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $976.86 | 2023-2025 | Viberzi, Linzess, Mavyret |
| Olympus Corporation of The Americas | $893.00 | 2019 | |
| Janssen Biotech, INC. | $398.14 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $328.10 | 2023-2025 | |
| Medtronic, INC. | $312.90 | 2023-2025 | Endoflip, Interstim, Pillcam |
| Ardelyx, INC. | $188.44 | 2023-2025 | Ibsrela |
| Endogastric Solutions, INC | $173.96 | 2024 | Esophyx |
| Phathom Pharmaceuticals, INC. | $143.69 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.64 | 2023-2025 | Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $128.96 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $124.12 | 2025 | |
| Cook Medical LLC | $121.25 | 2021 | |
| Boston Scientific Corporation | $114.66 | 2025 | Overstitch Endoscopic Suturing System |
| Madrigal Pharmaceuticals | $83.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $73.70 | 2024-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $59.60 | 2023-2024 | Zeposia |
| Shire North American Group INC | $57.54 | 2019 | |
| Genzyme Corporation | $56.52 | 2024-2025 | |
| Redhill Biopharma INC. | $42.05 | 2024 | Aemcolo, Talicia |
| Lucid Diagnostics INC. | $40.18 | 2023 | |
| Braintree Laboratories, INC. | $23.14 | 2023 | Sutab |
| Merck Sharp & Dohme LLC | $18.06 | 2019 | |
| Novo Nordisk INC | $14.68 | 2025 | Wegovy |
| Shield Therapeutics INC | $14.38 | 2023 | Accrufer |
| Optos, INC. | $13.53 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dentsply Ih Ab | $13.08 | 2024 | Navina Rectal Catheter Set Regular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.